The pharmaceutical industry is grappling with pressures including changing business models, a more competitive market, shifts in customers’ demands (e.g., patients and providers), major patent expiries, shifting technology, constrained budgets, increasing scrutiny from payers and regulators, and fundamental questions regarding the industry’s integrity. Many of these internal and external pressures…
Bio/pharmaceutical companies in the United Kingdom have recently been struggling to convince the National Institute for Health and Care Excellence (NICE) that their products are worth the price. “Although obinutuzumab is a clinically effective treatment, there were too many uncertainties in the company’s submission and we cannot be confident that…
Manufacturers exploring opportunities in global markets face dynamic demographic and disease trends, changing market demands, and evolving regulatory requirements—all of which differ from one country to another. While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still…
Recognizing that emerging markets continue to play a significant role in terms of future growth, most major pharmaceutical companies have accelerated efforts to strengthen their presence within these markets through R&D investment, licensing deals, acquisitions, or other partnerships. However, with global markets facing dynamic demographic and disease trends, changing market…
The Middle East has been rocked in recent years by upheaval. While the potential for disruption is real, the region has been characterized as well by rapid growth in the healthcare sector. One of its brightest lights is Israel. It is a developed, industrialized nation that, despite ongoing conflict with…
It was less than a decade ago that most pharmaceutical manufacturers considered market access the last step in the commercialization process… maybe even something that happened post-launch! However it has become increasingly clear that this approach must change. Companies exploring opportunities in global markets face dynamic demographic and disease trends,…
